Oncology Blog

Clinical scope and interpretation of the official MSKCC DCIS Nomogram.

Clinical scope and interpretation of the official MSK postoperative gastric nomogram.

Compare original IPSET-Thrombosis, revised IPSET-Thrombosis, and conventional ET thrombosis risk factors.

Compare MASCC Risk Index and CISNE for low-risk febrile neutropenia assessment.

Source-specific GHSG HD10/HD11-era and EORTC/GELA H9-U definitions for early-stage classical Hodgkin lymphoma.

When to use PLCOm2012 versus Brock, Mayo, Herder, and Lung-RADS in lung screening and nodule workflows.

Use CTS5 to estimate 5-10 year late distant recurrence risk after endocrine therapy in ER-positive early breast cancer.

What CanRisk and BOADICEA estimate, when to use them instead of Gail/BCRAT, and where clinicians can access the official tool.

Clinical guide to Tyrer-Cuzick/IBIS, key inputs, limitations, and when it is preferred over Gail/BCRAT.

Compare Gail/BCRAT, Tyrer-Cuzick/IBIS, and CanRisk/BOADICEA for breast cancer risk estimation.

Compare PREDICT Breast, CTS5, Oncotype DX, and related breast prognosis tools.

Guide to NCI DCEG colorectal cancer five-year cancer-specific survival probability tools and related colorectal calculators.

Compare Peritoneal Carcinomatosis Index and Completeness of Cytoreduction score in CRS-HIPEC workflows.

Compare G8, CARG, CARG-BC, CRASH, and Charlson tools for older adults being considered for chemotherapy.

A comprehensive guide to the RTOG RPA classification for brain metastases, including clinical evidence, survival data, and the OncoToolkit calculator logic.

Accurately stratify Mantle Cell Lymphoma risk using the MIPI score. A complete guide for clinicians on prognostic variables, survival estimates, and treatment integration.

Source-locked FIGO 2009 clinicopathologic risk-group interpretation when molecular classification is unknown or unavailable.

A professional guide for breast surgeons on using the Gail Model (BCRAT) to estimate 5-year and lifetime breast cancer risk for ri screening.

Learn how the mGPS quantifies systemic inflammation to predict outcomes in gastrointestinal and solid-organ cancers using CRP and albumin.

Estimate prostate cancer recurrence risk in seconds. Use age, PSA, Gleason, clinical stage, and biopsy cores to stratify risk and support treatment decisions.

Master the Milan Criteria for HCC liver transplant selection. Explore clinical evidence, regional validation, and how to use digital tools for MDT decision support.

Keep AJCC Breast 8th Edition staging contexts separate and use authoritative licensed staging sources.

Rapidly identify vulnerability in older cancer patients with the G8 Screening Tool. Access our clinical calculator to streamline CGA referrals and optimize treatment planning.

A source-locked guide to interpreting a final Exact Sciences Colon Recurrence Score without calculating assay output, recurrence probability, or treatment benefit.

Maximize patient selection accuracy for Phase I oncology trials with the RMH Score. Use our clinical calculator to stratify risk and estimate median overall survival.

Use the Brock (PanCan) model to quantify lung nodule malignancy risk. This guide covers calculation logic, BTS/Fleischner integration, and clinical use cases.

A comprehensive guide to the NCCN-IPI for DLBCL. Learn how refined age, LDH, and extranodal site factors improve 5-year survival estimates in the rituximab era.

Estimate grade 3–5 chemotherapy toxicity risk in older adults using the evidence-based CARG model, aligned with ASCO and NCCN geriatric oncology guidelines.

Master metastatic RCC risk stratification with the MSKCC (Motzer) Score. Learn how this 5-factor model predicts survival and guides systemic therapy.

A comprehensive guide on evaluating high-risk features in Stage II colon cancer to inform adjuvant chemotherapy decisions using evidence-based clinical criteria.

Interpret the original 1989 Mirels score, historical cohort observations, score-8 source conflict, and applicability limits without automated treatment advice.

Review the exact PPI weights, overlapping >4 and >6 thresholds, original performance metrics, and PPSv2 caveat.

Calculate Classic IPI and NCCN-IPI for DLBCL side-by-side. Get instant risk group stratification and 5-year OS estimates for diffuse large B-cell lymphoma.

Learn how to use the MASCC Risk Index to stratify febrile neutropenia risk and determine if outpatient management is safe for cancer patients.

A comprehensive guide and clinical calculator for the Palliative Prognostic (PaP) Score, providing validated 30-day survival estimates for terminally ill cancer patients.

A comprehensive guide to using the SINS (Spinal Instability Neoplastic Score) calculator to assess mechanical stability in neoplastic spine disease and guide surgical referrals.

Calculate the original ELTS baseline prognostic score for newly diagnosed chronic-phase CML before treatment.

A guideline-aligned BCLC staging system calculator for HCC, reflecting 2022 updates. Access rapid decision support for clinical staging and treatment allocation.

A clinical guide to the RCC Prognosis Panel, integrating IMDC and MSKCC risk models for precision systemic therapy decision-making.

Review the current OPTN Policy 9.1.D calculated MELD formula, exact input handling, branch rules, and deliberate allocation-scope limits.

Accurately stratify localized prostate cancer risk using PSA, Gleason score, and T stage with our guideline-aligned D’Amico Risk Classification calculator.

Master the FLIPI score for follicular lymphoma. Access our clinical calculator, explore survival data, and learn how to integrate risk stratification into practice.

An evidence-based guide and calculator for VTE risk stratification in ambulatory cancer patients using the Khorana Score criteria and ASCO/ITAC guidelines.

An evidence-based guide to using the CISNE score for risk-stratifying stable febrile neutropenia patients with solid tumors.

A clinical guide on using the MACIS score to estimate 20-year cause-specific survival in papillary thyroid carcinoma patients.

Source-specific guide to the original 1982 three-group Nottingham Prognostic Index for complete postoperative invasive breast cancer pathology.

Use the Graded Prognostic Assessment (GPA) calculator to estimate survival in brain metastases and align treatment with EANO-ESMO and NCCN guidelines.

Estimate myelofibrosis survival and risk in seconds with the DIPSS calculator. Optimize transplant and JAK inhibitor decisions at the point of care.

A concise guide to the original 2012 basic IPSS-R for primary untreated MDS, including exact thresholds, scope, and historical outcomes.

Explore guideline‑consistent uses of the iMODEL (Ovarian Recurrence) calculator, featuring trial data, practice statements, and PET/CT selection strategies.

A clinical guide to using the RMI I score for ovarian mass triage, including CA125 interpretation and ultrasound morphology scoring.

Master R-ISS staging for multiple myeloma. Learn how to integrate ISS, LDH, and FISH cytogenetics into clinical practice using our guideline-aligned calculator.

A guide to the original IPI score, its five adverse factors, historical pre-rituximab outcomes, and prognostic use in aggressive non-Hodgkin lymphoma.

Learn how the ALBI Score provides an objective, laboratory-based assessment of liver function in HCC patients using only albumin and bilirubin levels.

A comprehensive guide to using the Myeloma Master Panel to integrate R2-ISS disease biology with IMWG frailty scores for precision treatment decisions.

A source-specific guide to the separate original UCSF-CAPRA and historical Johns Hopkins Epstein cT1c panel outputs.

A comprehensive guide to using the Lung Nodule Malignancy Risk Panel, integrating Mayo, Brock, and Herder models for evidence-based clinical decisions.

Accurately differentiate benign adrenal adenoma from adrenocortical carcinoma using the validated nine-parameter Weiss Score histologic system.

A comprehensive guide to using the ESAS-r Symptom Score to streamline palliative care assessment for pain and cancer specialists.

Compare Child-Pugh, ALBI, OPTN Calculated MELD 3.0, BCLC 2026, original HKLC-9, and Milan outputs without a combined treatment recommendation.

A comprehensive clinical guide on integrating MASCC and CISNE scores for rapid, evidence-based triage of febrile neutropenia.

Calculate individualized 6-year lung cancer risk with the PLCOm2012 model. Enhance LDCT screening accuracy and reduce clinical disparities.

Master Febrile Neutropenia triage using MASCC and CISNE scores. Optimize risk stratification and clinical decision-making for oncologic emergencies.

Calculate 5-year freedom from progression for advanced cHL with our IPS (Hasenclever) calculator. Optimized for rapid MDT and clinical decision support.

Use the official eviQ 3201 v3 calculator with its current opioid-conversion warnings and clinical safety boundaries.

Estimate CLL-IPI risk groups and 5-year survival for chronic lymphocytic leukemia patients to optimize clinical counseling and MDT decision-making.

Interpret a final external Breast Recurrence Score within separate TAILORx and RxPONDER source contexts without calculating treatment benefit.

Accurately stratify mRCC patients using the IMDC (Heng) Risk Score. Get survival benchmarks and risk categories to guide systemic therapy decisions.

Use the Revised Tokuhashi Score to estimate survival in spinal metastases and guide surgical planning with our clinical calculator.

Rapidly assess ECOG Performance Status and KPS. Use this clinical tool to guide oncology treatment decisions and trial eligibility at the point of care.

Standardize adnexal mass assessment with our O-RADS Ultrasound calculator. Get instant ACR-aligned risk categories and management suggestions.

Stratify thrombotic risk in Essential Thrombocythemia (ET) using the IPSET-Thrombosis score to guide aspirin and cytoreductive therapy decisions.

Interpret the original nine-category 2014 HKLC stage from exact tumor burden, IVI, EVM, ECOG, and Child-Pugh inputs without treatment recommendations.

View six verified source-specific components side by side without combined staging, treatment, prognosis, transplant, or agreement synthesis.

Interpret the standard-bilirubin CTP total and class using explicit INR or PT prolongation, strict scope and timing gates, and no survival or treatment directive.

A comprehensive guide to hepatocellular carcinoma staging systems and when to use each calculator.